Clinical Trial Detail

NCT ID NCT03136146
Title Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

lymphoid leukemia

lymphoblastic lymphoma

Burkitt lymphoma

Therapies

Cyclophosphamide

Bortezomib

Etoposide

Rituximab

Ofatumumab

Clofarabine

Pegfilgrastim

Age Groups: adult child senior

No variant requirements are available.